[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642719":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":27,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IV CBCT","EXPERIMENTAL",null,[13],"Diagnostic Test: Intravenous contrast-enhanced cone beam computed tomography",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","Intravenous contrast-enhanced cone beam computed tomography","Two half-arc IV-contrast enhanced CBCT scans and mpMRI seuqences in addition to their routine standard of care CBCT that is done as part of image-guided radiotherapy. These scans will be done during the second and last fraction of treatment.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Jelena Lukovic, MD FRCPC MPH MRMD","CONTACT","4169464501","4858","jelena.lukovic@uhn.ca",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Princess Margaret Cancer Center","RECRUITING","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":37,"coordinates":38},"Point",[39,40],-79.39864,43.70643,{"lat":40,"lon":39},[43],{"name":22,"role":23,"phone":44,"phoneExt":25,"email":45},"416-946-4501","Jelena.Lukovic@uhn.ca",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100642719","contrast-enhanced-cbct-with-c-arm-hypersight-technology-100642719",false,"NCT07648160","Contrast-enhanced CBCT With C-arm HyperSight Technology","Contrast-enhanced CBCT With C-arm HyperSight Technology: A Feasibility Study","IV-CBCT","Inclusion Criteria:\n\n* Primary biopsy-proven cancer\n* Planning to undergo spatially fractionated radiation therapy\n* Able to provide informed consent\n* Willingness to participate in follow-up\n* ECOG less than or equal to 3\n* Normal creatinine (below 109mmol\u002FL), normal eGF\n\nExclusion Criteria:\n\n* Unable to understand\u002Fprovide consent\n* History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria)\n* Known renal disease\n* Single kidney\n* Kidney transplant\n* Dialysis\n* Contraindication to MRI","ALL","18 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"NA","This is a single-arm prospective, feasibility study evaluating the intravenous contrast-enhanced cone beam computed tomography (IV CBCT) for image guidance during radiotherapy. Patients treated with SFRT will receive IV-contrast enhanced CT and fMRI before treatment for simulation purposes. Additionally, patients will receive mpMRI just before and IV-contrast enhanced CBCT during their second and last fraction of RT, in addition to the standard of care CBCT that is acquired for daily image-guided patient positioning. Patients will undergo both IV-contrast enhanced CBCT and treatment on the TrueBeam with HyperSight imaging capability. We hypothesize IV contrast enhanced CBCT is feasible, well-tolerated by patients and improves the visibility of the target.",[66],"Advanced Cancer",[68],"IV-contrast-enhanced CT","2026-06-24",{"date":71,"type":72},"2026-06-26","ACTUAL",{"date":69,"type":72},{"date":75,"type":60},"2027-07-01",{"name":5,"class":6},1]